NCT02222285 is a NA clinical trial of Medical Food : Vayarin_005 in Autistic Disorder, sponsored by Enzymotec.

Who is sponsoring NCT02222285?

NCT02222285 is sponsored by Enzymotec.

What drugs are being tested in NCT02222285?

Interventions in NCT02222285: Medical Food : Vayarin_005, Placebo.

What condition does NCT02222285 study?

NCT02222285 studies Autistic Disorder.

Is NCT02222285 still recruiting?

NCT02222285 is currently completed. Last updated 10 April 2018.

Last reviewed 2018-04-10 · How we verify

NCT02222285

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)

Completed NA Last updated 10 April 2018

What this trial tests

NA trial testing Medical Food : Vayarin_005 in Autistic Disorder in 56 participants. Completed in 1 October 2017.

Timeline

1 August 2014

Primary endpoint
1 May 2017

1 October 2017

Quick facts

Lead sponsor	Enzymotec
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	other
Enrollment	56
Start date	1 August 2014
Primary completion	1 May 2017
Estimated completion	1 October 2017
Sites	2 locations across United States

Drugs / interventions tested

Medical Food : Vayarin_005
Placebo

Conditions studied

Autistic Disorder — all drugs for Autistic Disorder →

Sponsor

Enzymotec

Who can join

Adults 6 to 17, any sex, with Autistic Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Aberrant Behavior Checklist will be used to asses Autism spectrum symptoms
Time frame: over 14 weeks
A significant reduction from baseline to endpoint on the Aberrant Behavior Checklist (ABC) compared to patients administered placebo

Sponsor's own description

The primary study objective is to evaluate the efficacy of Vayarin\_005 on ASD related symptoms in children.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Autistic Disorder

Currently open trials in the same condition.

NCT05910502 — Project AFECT (Autism Family Empowerment Coaching and Training Program) · NA · active not recruiting
NCT06227780 — Alpha Auditory Entrainment for Cognitive Enhancement and Sensory Hypersensitivity in Youth With Developmental Disorders · NA · recruiting
NCT05176808 — Telehealth Parent-Implemented Intervention for Young Children With Autism Spectrum Disorder (ASD) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02222285 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Enzymotec
Last refreshed: 10 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02222285.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing